Published in Asian J Androl on August 20, 2012
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1994) 17.37
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med (2005) 8.32
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Osteoporosis after orchiectomy for prostate cancer. J Urol (1997) 4.32
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2003) 3.82
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med (2001) 3.78
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer (2005) 3.56
Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest (2000) 2.94
Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol (2005) 2.87
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med (2007) 2.54
Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res (2004) 2.47
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab (2005) 2.23
NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA (1994) 2.03
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol (2010) 1.99
Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol (2002) 1.96
Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun (2005) 1.69
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol (2010) 1.66
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol (2004) 1.61
The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int (2006) 1.58
The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int (2007) 1.49
Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology (2004) 1.33
Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer (1997) 1.32
Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology (2007) 1.29
Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol (2008) 1.28
Risk factors for osteoporotic fracture. Endocrinol Metab Clin North Am (1998) 1.09
Osteoporosis and exercise. Postgrad Med J (2003) 0.94
Hip fractures in men with prostate cancer treated with orchiectomy. J Urol (2004) 0.93
Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol (2006) 0.93
The effects of smoking on bone mass and the rates of bone loss among elderly Japanese-American men. J Bone Miner Res (1997) 0.91
Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol (2011) 0.87
Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol (2003) 0.86
Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int (2003) 0.85
Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology (2009) 0.82
33% radius evaluation to assess bone mineral density in prostate cancer patients. World J Urol (2010) 0.76
[Arterial embolization in the treatment of renal trauma of a horseshoe kidney]. Arch Esp Urol (2005) 0.87
[Implantation technique of the artificial urinary sphincter "FlowSecure" in the bulbar urethra]. Arch Esp Urol (2009) 0.87
[Open versus laparoscopic pyeloplasty: review of our series and description of our laparoscopic pyeloplasty procedure]. Actas Urol Esp (2009) 0.84
Key areas in the learning curve for robotic urological surgery: a Spanish multicentre survey. Urol Int (2011) 0.82
[Closure of a neobladder-vaginal fistula in a patient with Studer's type neobladder using a transvaginal approach with interposition of a Martius' flap]. Arch Esp Urol (2009) 0.78
[Antimitogenic effect of Pygeum africanum extracts on human prostatic cancer cell lines and explants from benign prostatic hyperplasia]. Arch Esp Urol (2003) 0.77
[Editorial comment on how body mass index and diet affect the development of prostatic cancer]. Actas Urol Esp (2009) 0.75
[Measurement of complexed prostatic specific antigen. A new challenge in PSA era]. Med Clin (Barc) (2004) 0.75
[Kidney pelvis bifida]. Actas Urol Esp (2009) 0.75
[Laparoscopic radical cystectomy in clinically localized (T2) bladder tumors]. Arch Esp Urol (2008) 0.75
[Optimization of follow up in prostate cancer active surveillance]. Arch Esp Urol (2014) 0.75